Merck (SNSE:MRK) - Stock Price, News & Analysis

Resumen acción MRK

Merck & Co., Inc. opera como empresa sanitaria en todo el mundo.

MRK fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	1/6
Financial Health	4/6
Dividends	3/6

Recompensas

Cotiza un 46.2% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 24.95%

Análisis de riesgos

Volatilidad del precio de la acción en los últimos 3 meses

Grandes partidas extraordinarias que afectan a los resultados financieros

Los márgenes de beneficio (0.6%) son inferiores a los del año pasado (24.5%)

Venta significativa de accionistas con acceso a información confidencial en los últimos 3 meses

+ 1 riesgos adicionales

Competidores de Merck & Co., Inc.

Johnson & Johnson

NYSE:JNJ

US$355.5b

AstraZeneca

LSE:AZN

UK£171.5b

Novartis

SWX:NOVN

CHF188.6b

Novo Nordisk

CPSE:NOVO B

kr.3.9t

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Merck
Historical stock prices
Current Share Price	US$119.99
52 Week High	US$121.19
52 Week Low	US$103.74
Beta	0.40
1 Month Change	0%
3 Month Change	15.66%
1 Year Change	9.28%
3 Year Change	60.74%
5 Year Change	42.81%
Change since IPO	157.32%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	MRK	CL Pharmaceuticals	Mercado CL
7D	0%	0%	0%
1Y	9.3%	0%	0%

Rentabilidad frente al sector: MRK superó al sector CL Pharmaceuticals , que obtuvo un rendimiento del -24.1% el año pasado.

Rentabilidad vs. Mercado: MRK obtuvo unos resultados inferiores a los del mercado CL, que fue del 18.4% el año pasado.

Volatilidad de los precios

Is MRK's price volatile compared to industry and market?
MRK volatility
MRK Average Weekly Movement	4.0%
Pharmaceuticals Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in CL Market	0%
10% least volatile stocks in CL Market	0%

Precio estable de las acciones: MRK no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: MRK(4%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de CL.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1891	71,000	Rob Davis	www.merck.com

Merck & Co. opera como empresa de asistencia sanitaria en todo el mundo. Opera a través de dos segmentos: Farmacéutico y Salud Animal. El segmento Farmacéutico ofrece productos farmacéuticos para la salud humana en las áreas de oncología, cuidados agudos hospitalarios, inmunología, neurociencia, virología, cardiovascular y diabetes bajo las marcas Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi y Januvia, así como productos vacunales consistentes en vacunas preventivas pediátricas, para adolescentes y adultos bajo las marcas Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23 y Vaqta.

Resumen de fundamentos de Merck & Co., Inc.

¿Cómo se comparan los beneficios e ingresos de Merck con su capitalización de mercado?
Estadísticas fundamentales de MRK
Capitalización bursátil	US$318.50b
Beneficios(TTM)	US$365.00m
Ingresos (TTM)	US$60.12b

872.6x

Ratio precio-beneficio (PE)

5.3x

Ratio precio-ventas (PS)

¿Está MRK sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de MRK
Ingresos	US$60.12b
Coste de los ingresos	US$15.92b
Beneficio bruto	US$44.20b
Otros gastos	US$43.84b
Beneficios	US$365.00m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

Apr 25, 2024

Beneficios por acción (BPA)	0.14
Margen bruto	73.53%
Margen de beneficio neto	0.61%
Ratio deuda/patrimonio	93.1%

¿Cómo se ha desempeñado MRK a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

2.4%

Rentabilidad actual por dividendo

2,030%

Ratio de pagos

Resumen acción MRK

Recompensas

Análisis de riesgos

Competidores de Merck & Co., Inc.

NYSE:JNJ

US$355.5b

LSE:AZN

UK£171.5b

SWX:NOVN

CHF188.6b

CPSE:NOVO B

kr.3.9t

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Announces Positive Data on V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Merck Announces its KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Recent updates

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Announces Positive Data on V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Merck Announces its KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Upcoming dividend of US$0.77 per share

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Full year 2023 earnings released: EPS: US$0.14 (vs US$5.73 in FY 2022)

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Merck & Co., Inc., Annual General Meeting, May 28, 2024

FDA Grants Priority Review to Merck's Application for Keytruda (Pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Health Canada Approves Keytruda® in Combination with Trastuzumab and Chemotherapy, as A First-Line Treatment for Patients with Locally Advanced Her2-Positive Gastric or Gastric or Gastroesophageal Junction Adenocarcinoma

Executive VP & General Counsel recently sold US$3.8m worth of stock

Full year 2023 earnings released: EPS: US$0.14 (vs US$5.73 in FY 2022)

Third quarter dividend of US$0.77 announced

Merck Announces Results from the Phase 3 AMBASSADOR (A031501/KeyNOTE-123 Trial Evaluating KEYTRUDA

Merck Declares Dividend for the Second Quarter of 2024, Payable on April 5, 2024

Merck & Co., Inc. Announces FDA Approves Merck's KEYTRUDA® (Pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients with FIGO 2014 Stage III-IVA Cervical Cancer

Merck Reportedly in Talks to Buy Harpoon Therapeutics

Merck & Co., Inc. Announces Phase 3 Trial Initiations for Four Investigational Candidates from Its Promising Hematology and Oncology Pipeline

FDA Grants Priority Review to Merck's New Biologics License Application for V116

Merck Announces FDA Approves Expanded Indication for KEYTRUDA (pembrolizumab) Plus Padcev for the First-Line Treatment of Adult Patients with Locally Advanced or Metastatic Urothelial Cancer

Merck and Moderna Initiates INTerpath-002, A Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with Keytruda® (Pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Upcoming dividend of US$0.77 per share at 2.8% yield

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

Merck & Co., Inc. Announces Management Changes, Effective on December 4, 2023

Merck & Co., Inc. (NYSE:MRK) entered into definitive agreement to acquire an unknown stake in Caraway Therapeutics, Inc. from AbbVie Ventures, Inc., SV Health Investors, LLC,Dementia Discovery LP, Amgen Ventures and Eisai Innovation Inc. for $610 million.